A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Inclusion Criteria:

- Have type 2 diabetes mellitus (T2DM).

- Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to
screening, with or without basal insulin.

- If currently on basal insulin, must be taking LANTUS® QD or NPH or insulin detemir
either QD or twice a day for at least 90 days prior to study entry.

- Have an HbA1c ≥7.0% and ≤11.0% if insulin naïve; if previously on basal insulin, then
HbA1c ≤11.0%.

- Body mass index (BMI) ≤45 kilograms per meter squared (kg/m^2).

- As determined by the investigator, are capable and willing to do the following:

- perform self monitored blood glucose (SMBG)

- complete participant diaries as instructed

- are receptive to diabetes education

- comply with required study treatment and study visits

Exclusion Criteria:

- Have been on LANTUS® more than once daily within the previous 30 days.

- Have used any other insulin except the entry insulin [LANTUS®, insulin detemir, or
NPH] including commercial (includes any premixed insulins) and investigational
insulins within the previous 30 days.

- Have been exposed to a biosimilar insulin glargine within the previous 90 days.

- Have participated in a LY2963016 study.

- Have taken basal plus mealtime insulin (basal bolus therapy) within the last year for
greater than 4 continuous weeks.

- Have used any glucagon like peptide (GLP-1) receptor agonists within the previous 90
days.

- Have used pramlintide within the previous 30 days.

- Have excessive insulin resistance at study entry (total insulin dose ≥1.5 units/kg).

- Have more than 1 episode of severe hypoglycemia within 6 months prior to screening.

- Have had 2 or more emergency room visits or hospitalizations due to poor glucose
control in the 6 months prior to screening.

- Have known hypersensitivity or allergy to LANTUS® or its excipients.

- Are receiving chronic (lasting longer than 14 consecutive days) systemic
glucocorticoid therapy or have received such therapy within 4 weeks immediately
preceding screening.

- Have obvious signs or symptoms, or laboratory evidence, of liver disease.

- Have one of the following concomitant diseases: significant cardiac (e.g., congestive
heart failure Class III or IV) or gastrointestinal disease (e.g., significant
gastroparesis).

- Have a history of renal transplantation or are currently receiving renal dialysis.

- Have a serum creatinine greater than 2.0 milligrams/deciliter (177 micromoles/liter).

- Have had a blood transfusion or severe blood loss within 3 months prior to screening
or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.

- Participants with active cancer or personal history of cancer within the previous 5
years (with the exception of basal cell carcinoma or carcinoma in situ).

- Have a history or diagnosis of Human Immunodeficiency Virus (HIV) infection.

- Have any other condition (including known drug or alcohol abuse or psychiatric
disorder including dementia) that precludes the participant from following and
completing the protocol.

- Are pregnant or intend to become pregnant during the course of the study.

- Women who are breastfeeding.

- Are currently enrolled in, or discontinued within the last 30 days from, a clinical
trial involving an investigational product or non-approved use of a drug or device
other than LY2963016, or concurrently enrolled in any other type of medical research
judged not to be scientifically or medically compatible with this study.